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Type 2 (non-insulin-dependent) diabetes mellitus is
a progressive metabolic disorder arising from genetic
and environmental factors that impair beta cell func-
tion and insulin action in peripheral tissues. We
identified reduced diacylglycerol kinase d (DGKd) ex-
pression and DGK activity in skeletal muscle from
type 2 diabetic patients. In diabetic animals, reduced
DGKd protein and DGK kinase activity were restored
upon correction of glycemia. DGKd haploinsufficiency
increased diacylglycerol content, reduced peripheral
insulin sensitivity, insulin signaling, and glucose trans-
port, and led to age-dependent obesity. Metabolic
flexibility, evident by the transition between lipid
and carbohydrate utilization during fasted and fed
conditions, was impaired in DGKd haploinsufficient
mice. We reveal a previously unrecognized role for
DGKd in contributing to hyperglycemia-induced pe-
ripheral insulin resistance and thereby exacerbating
the severity of type 2 diabetes. DGKd deficiency
causes peripheral insulin resistance and metabolic
inflexibility. These defects in glucose and energy
homeostasis contribute to mild obesity later in life.
INTRODUCTION
Type 2 diabetes constitutes a burgeoning epidemic, which is ex-
pected to afflict over 300 million individuals world-wide by 2015
(Zimmet et al., 2001). Characteristic features include glucose
intolerance, insulin resistance, hyperglycemia, and often hyper-
insulinemia (Biddinger and Kahn, 2006). Skeletal muscle insulinresistance and impaired beta cell function (Eriksson et al.,
1989), arising from a combination of genetic and environmental
factors (Florez et al., 2003; Laakso, 2005), are necessary for
the development of type 2 diabetes. Although available therapies
fail to completely normalize glycemia and insulin sensitivity in the
long-run (Moller, 2001), aggressive control of hyperglycemia
partly improves whole-body insulin sensitivity and skeletal mus-
cle glucose uptake (Rossetti et al., 1990; Zierath et al., 1994) and
attenuates the development of chronic complications such
as retinopathy, nephropathy, and neuropathy (UK Prospective
Diabetes Study Group, 1998).
Diacylglycerol (DAG) plays a role in lipid metabolism as a pre-
cursor of triglycerides and phospholipids and acts as a second
messenger in cellular signaling. In rodents, glucose-induced
insulin resistance is associated with a temporal increase in intra-
cellular DAGmass (Kraegen et al., 2006). A persistent increase in
intracellular DAG promotes intracellular lipid accumulation and
aberrant signal transduction through activation of protein kinase
C (PKC) isoforms and insulin resistance (Itani et al., 2002; Montell
et al., 2001). The underlying mechanism for DAG-induced insulin
resistance is incompletely understood, but increased PKC-
mediated serine phosphorylation of the insulin receptor (IR)
and insulin receptor substrate 1 (IRS-1) and subsequent downre-
gulation of glucose transport are implicated (Yu et al., 2002).
DAG is also phosphorylated to form phosphatidic acid (PA) to
act as a lipid second messenger to regulate signals involved in
metabolic and mitogenic responses, including phosphatidylino-
sitol 4-phosphate 5-kinase, PKCz, and the mammalian target of
rapamycin (Avila-Flores et al., 2005; Luo et al., 2004). Intracellu-
lar DAG and PA levels are tightly controlled, and disturbances in
this balance may impair cellular metabolism.
Phosphorylation of DAG to PA is catalyzed by diacylglycerol
kinases (DGK), a family of enzymes acting as key attenuators
of DAG signaling (Kanoh et al., 2002). DGK isoforms are ofCell 132, 375–386, February 8, 2008 ª2008 Elsevier Inc. 375
relevance for insulin action because DAG accumulation is asso-
ciated with insulin resistance and impaired glucose uptake in
skeletal muscle (Montell et al., 2001). Ten mammalian DGK iso-
forms have been classified into five subgroups based on primary
structure (Sakane et al., 2007). DGK isoforms including a, d, 3,
and z are expressed in skeletal muscle, suggesting isoform-spe-
cific function (Topham, 2006; van Blitterswijk and Houssa, 2000).
DGKs play a critical role in depleting DAG/increasing PA at
specific intracellular sites, including plasma membrane, endo-
plasmic reticulum, Golgi apparatus, and nuclei (Nagaya et al.,
2002; Topham et al., 1998). The direct role of DGK isoforms in
the development of insulin sensitivity and diabetes mellitus is
unknown.
We used oligonucletide microarrays to identify defects in skel-
etal muscle from type 2 diabetic patients by examining gene-
expression profiles (E-MEXP-1270). This revealed that DGKd is
downregulated in skeletal muscle from poorly controlled type 2
diabetic patients (Table S1 available online). DGKdwas originally
cloned from a human testis library and is highly expressed in
skeletal muscle (Sakane et al., 1996). A previousmicroarray anal-
ysis of vastus lateralismuscle from individuals participating in the
HERITAGE Family Study shows that DGKd expression was
increased in people who exhibited enhanced insulin sensitivity
after exercise training (Teran-Garcia et al., 2005), suggesting
that increased skeletal muscle DGKd expression may be a
marker of improved insulin action.
We show that DGKd protein expression and total DGK activity
are reduced in skeletal muscle from type 2 diabetic patients and
diabetic rodents and normalized upon correction of hyperglyce-
mia. Reduced DGKd activity, either by chemical inhibition or by
genetic ablation of the enzyme using DGKd haploinsufficient
mice, causes aberrant insulin signaling, glucose uptake defects
in skeletal muscle and adipose tissue, impaired whole-body in-
sulin sensitivity, and obesity. Our findings suggest a previously
unrecognized role for DGKd hyperglycemia-induced peripheral
insulin resistance. Reduced DGKd may exacerbate the severity
of type 2 diabetes.
RESULTS
Skeletal Muscle DGKd Protein Content and Activity Is
Reduced in Type 2 Diabetes
We determined DGKd protein expression in lysates prepared
from vastus lateralis skeletal muscle biopsies obtained from 11
type 2 diabetic and 11 nondiabetic participants with fasting
blood glucose of 9.9 ± 1.2 and 5.3 ± 0.2 mmol/l, respectively.
The clinical characteristics for this cohort are presented in Table
S2. Skeletal muscle DGKd protein expression was reduced 37%
(Figure 1A; p < 0.05) in type 2 diabetic subjects, while DGKa, 3,
and z protein was unaltered (Figure 1B). Total skeletal muscle
DGK activity was markedly decreased in type 2 diabetic patients
(Figure 1C), suggesting that DGKd is the predominantly
expressed DGK isoform contributing to total DGK activity in
human skeletal muscle. Skeletal muscle DGKd protein expres-
sion was negatively correlated with fasting blood glucose
(r = 0.50; p < 0.01) and HbA1C (r = 0.60; p < 0.05) and tended
to correlate with body mass index (r = 0.31; p = 0.08) and
whole-body glucose utilization (r = 0.43; p = 0.06), but not fasting376 Cell 132, 375–386, February 8, 2008 ª2008 Elsevier Inc.insulin or percentage body fat (Figure S1). In a similar cohort of
type 2 diabetic patients, skeletal muscle IR, IRS-1, IRS-2, MAP
kinase, glycogen synthase, and glucose transporter 4 (GLUT4)
protein content was unchanged, despite impairments in insulin
signaling and glucose uptake (Krook et al., 2000).
We hypothesized that DGKd protein expression may be di-
rectly related to the level of glycemia. We determined whether
hyperglycemia directly downregulates DGKd protein expression
in cultured human skeletal muscle from 5 nondiabetic partici-
pants incubated with either 5.5 mM or 25 mM glucose for 96 hr
(Figure 1D). DGKd protein expression was downregulated in my-
otubes exposed to 25 mM glucose, while protein expression of
DGKz was unaltered. To assess whether changes in glycemia
regulate DGKd expression in vivo, we studied skeletal muscle
fromGoto Kakizaki (GK) rats, a nonobese normolipidemic animal
model of type 2 diabetes developed by selective breeding of glu-
cose-intolerant Wistar rats over several generations. This animal
model is characterized by hyperglycemia and peripheral insulin
resistance, primarily due to a beta cell defect (Portha, 2005).
Rats were treated for 4 weeks with phlorizin (phloretin-20-b-glu-
coside), an inhibitor of renal glucose reabsorption to normalize
glycemia, glucose tolerance, and insulin sensitivity (Krook
et al., 1997; Song et al., 1999). Skeletal muscle DGKd protein ex-
pression was decreased by 35% (p < 0.05) in GK rats versus
nondiabetic Wistar rats (Figure 1D). In contrast, DGKz and a pro-
tein expression in GK rats was unaltered (Figure S2), consistent
with our human study, highlighting that the DGKd isoform is
specifically downregulated in diabetes. Phlorizin treatment in
diabetic GK rats normalized glycemia and restored DGKd protein
expression. Total DGK activity (Figure 1E) and DAG mass
(Figure 1F) were measured. Total DGK activity was decreased
and intracellular DAG mass was increased in skeletal muscle
fromdiabetic GK rats, indicating that the DGKd isoform is amajor
contributor to total DGK activity in rodent skeletal muscle.
Normalization of glycemia in phlorizin-treated GK rats restored
skeletal muscle DGK activity and DAG mass. Conversely, liver
expression of DGKd and DAG mass was similar between Wistar
and GK rats treated with either vehicle or phlorizin (Figure S3). In
fat-fed Wistar rats, which display peripheral insulin resistance
and glucose intolerance but not hyperglycemia, skeletal muscle
DGKd protein expression was unaltered (Figure 1H). Thus, hy-
perglycemia directly influences DGKd protein expression, DGK
activity, and DAG mass in skeletal muscle but not liver.
Inhibition of DGK Activity Decreases Glucose Transport
through a DAG-cnPKC Pathway
Alterations in skeletal muscle DGK activity change the local
concentration of DAG and PA, which may subsequently influ-
ence insulin signaling and metabolism. We determined whether
inhibition of DGK alters insulin action in intact rat epitrochlearis
muscle using two pan-DGK class I inhibitors, R59949 or R59022
(Jiang et al., 2000). These inhibitors bind to the catalytic domain
of DGK isoforms and inhibit kinase activity. Incubation of rat
epitrochlearis muscle with R59949 or R59022 decreased total
DGK activity (Figure 2A) and increased DAG levels (Figure 2B),
highlighting an inverse relationship between DGK activity and
DAG accumulation in skeletal muscle. In parallel with the
DAG accumulation, conventional/novel PKC (cnPKC) activity
Figure 1. Skeletal Muscle DGKd Protein Expression and DGK Activity Is Reduced in Type 2 Diabetic Patients and Hyperglycemic Diabetic
GK Rats
(A and B) Skeletal muscle lysates from type 2 diabetic (n = 11) and nondiabetic (n = 11) participants were subjected to immunoblot analysis using an antibody
against DGKd (A). Upper panel is representative image and lower panel is mean ± SEM, arbitrary units. *p < 0.05 versus control. Representative immunoblot
analysis (B) for DGKa, DGK3, DGKz, and actin (loading control) is shown.
(C) Total DGK activity in skeletal muscle homogenates from type 2 diabetic and controls. Upper panel is representative autoradiogram of phosphatidic acid (PA)
production, lower panel mean ± SEM, arbitrary units.
(D) DGKd and DGKz protein expression in primary human myotubes exposed to 5.5 or 25 mM glucose. *p < 0.05 versus 5.5 mM glucose.
(E–G) Gastrocnemius muscle from Wistar and GK rats after 4 week treatment with phlorizin (phl) or saline (n = 5–6 rats). Shown are DGKd and actin protein
expression (E), Total DGK activity (F), DAG content (G). *p < 0.05 versus Wistar.
(H) DGKd protein in gastrocnemius muscle from Wistar rats fed chow or high-fat diet for 4 weeks. *p < 0.05 versus chow-fed.
For (D)–(H), upper panel is representative image and lower panel mean ± SEM, arbitrary units.(Figure 2C) and isoform-specific phosphorylation of PKCd
(Figure 2D) were increased. DGK inhibition did not alter IR tyro-
sine phosphorylation (Figure 2E) but increased IRS-1 Ser307
and Ser302 phosphorylation (Figures 2F and 2G), implicating
DAG-induced PKC activity in the negative regulation of insulin
signaling. Indeed, insulin action on IRS-1 tyrosine phosphoryla-
tion, IRS-1-associated phosphatidyl inositol (PI) 3-kinase activ-
ity, and Akt/PKB kinase phosphorylation was impaired in muscle
exposed to the DGK inhibitors (Figure 2H). DGK inhibition also
reduced insulin-stimulated glucose transport in isolated rat epi-
trochlearis muscle (Figures 2I and 2J). To directly explore a role
of DAG-induced PKC-mediated insulin resistance,muscleswere
coincubated with R59949 and the broad spectrum PKC inhibitor
GF109203X (Figures 2H and 2I). Under these conditions, insulin
action on IRS-1, PI 3-kinase, Akt, and glucose transport was
restored. These results implicate increased DAG levels and
PKC activity in the regulation of the insulin response.
To address whether the effect of DGK inhibitors on glucose
transport is due to reduced insulin signaling or downstreameffects on GLUT4 trafficking or activity, epitrochlearis muscle
was exposed to hypoxia (Figure 2J), an insulin-independent
mediator of GLUT4 translocation and glucose transport (Cartee
et al., 1991). Hypoxia-mediated glucose transport was unaltered
in muscle coincubated with R59949; thus DGK inhibition does
not appear to directly alter GLUT4 traffic. Moreover, GLUT4
protein expression was unaltered in muscle exposed to DGK
inhibitors (data not shown).
To exclude a possible direct inhibitory effect of R59949 on
other kinases along the insulin signaling pathway, a specificity
test of the R59949 was performed against a panel of 30 protein
kinases in an in vitro assay (Bain et al., 2003; Davies et al., 2000).
Among these kinases, only serum and glucocorticoid regulated
kinase (SGK) was considerably inhibited by R59949 (Figure S4).
The specificity assays were conducted at an ATP concentration
far lower than that which is present in cells. Since R59949 is likely
to be an ATP competitive inhibitor, this compound is expected to
be a far weaker inhibitor of SGK1 in cells. Indeed, phosphoryla-
tion of NDRG1, a specific substrate of SGK expressed in skeletalCell 132, 375–386, February 8, 2008 ª2008 Elsevier Inc. 377
Figure 2. DGK Inhibition Attenuates Insulin Action in Rat Muscle
Isolated epitrochlearis muscle (n = 6–11) was incubated in the absence or in presence of 2.4 nM insulin and/or 25 mMR59949, 50 mMR59022, and/or 1 mMof PMA.
Muscle homogenates were prepared for (A) total DGK activity, (B) DAG content, and (C) combined conventional and novel PKC activity analysis. Lysates were
subjected to immunoblot analysis for (D) PKCd Thr505 phosphorylation, (E) IR tyrosine phosphorylation, (F) IRS-1 Ser307 phosphorylation, and (G) IRS-1 Ser302
phosphorylation. Skeletal muscle was also incubated (H–I) in the absence or presence of 1 mM PMA, 1 mM GF109203X, 25 mM R59949, or 50 mM R59022. (H)
IRS-1 tyrosine phosphorylation, PI 3-kinase activity, Akt Ser473 phosphorylation, and (I–J) 3-O-methyl-glucose transport were assessed. Upper panel is
representative image. Lower panel is mean ± SEM, *p < 0.05 versus non-insulin-stimulated control. #p < 0.05 versus insulin-stimulated.muscle (Murray et al., 2004), was unaffected by the concentra-
tions of R59949 used in this study. Moreover, skeletal muscle
SGK protein expression was unaltered between type 2 diabetic
versus control subjects, or Wistar versus diabetic GK rats. Addi-
tion of R59949directly to the assay buffer did not alter PI 3-kinase
activity (Figure S4). Thus, the impairment in insulin signaling and
glucose uptake is likely a direct consequence of DGK inhibition.
DGK Protein Expression and Activity in DGKd
Haploinsufficient Mice
As there are several DGK isoforms expressed in skeletal muscle
(a, d, 3, and z), we cannot completely resolve whether chemical
inhibitors of DGK activity will confer the same phenotype as
DGKd isoform-specific inhibition. The DGK activity inhibited by378 Cell 132, 375–386, February 8, 2008 ª2008 Elsevier Inc.either R59949 or R59022 is primarily derived from class I DGK
isoforms (Jiang et al., 2000). Although theDGK isoforms inhibited
by either R59949 or R59022 appear to affect insulin signaling and
glucose uptake, only DGKd, a class II DGK isoform, was reduced
in type 2 diabetic patients and diabetic GK rats. To determine
whether the reduction in DGKd protein expression in skeletal
muscle from type 2 diabetic patients is of direct physiological
relevance for altered glucose homeostasis, we metabolically
characterized heterozygous DGKd whole-body knockout mice.
DGKd+/ mice were generated as described (Crotty et al.,
2006). Inhibition of DGK activity by R59949 in skeletal muscle
homogenates from either Wistar and GK rats or wild-type (WT)
and DGKd+/ mice indicates that the DGKd isoform accounts
for approximately 60% of total DGK activity (Figure S5).
DGKd+/ mice have a 50% reduction in DGKd protein in skel-
etal muscle (Figure 3A), which is similar to the 37% reduction in
skeletal muscle DGKd protein expression in type 2 diabetic
patients (Figure 1A). DGKd protein expression in fat and liver of
DGKd+/ mice was also reduced (Figures 3B and 3C). Total
DGK activity was reduced in skeletal muscle and fat but not liver
(Figure 3D). Total DGK activity in homogenates and a crude
membrane fraction obtained from gastrocnemius muscle from
DGKd+/ mice was reduced, while DGK activity in the cytoplas-
mic fraction was unaltered (Figure 3E). The decrease in DGK ac-
tivity in the membrane fraction in DGKd+/ mice highlights the
potential importance of the membrane localization of DGKd
signaling. DGKd contains a PHdomain and has been found in en-
doplasmic reticulum and Golgi apparatus (Nagaya et al., 2002).
Subcellular fractionation of rat gastrocnemius muscle revealed
that DGKd protein is mainly associated with intracellular mem-
branes (data not shown).
DGKd Haploinsufficiency Leads to Development
of Glucose Intolerance and Obesity
Age is an important risk factor for the development of skeletal
muscle insulin resistance and type 2 diabetes (Nair, 2005).
Thus, DGKd+/mice were studied at 9 or 36 weeks. Blood chem-
istry for DGKd+/ andWT littermates is presented (Table S3). At 9
weeks, body weight and epidydimal fat pad weight were
unaltered in DGKd+/ mice (Figure 4A). However, at 36 weeks,
body weight and epidydimal fat pad weight were increased in
DGKd+/ mice, concomitant with increase in plasma leptin
concentration (Table S3). Plasma resistin concentration was un-
altered in DGKd+/ mice but significantly increased at 36 week
regardless of genotype (Table S3). Plasma adiponectin levels
were unaltered between DGKd+/ and WT mice (Table S3).
An intraperitoneal glucose tolerance test (IPGTT)wasperformed
at 9 and 36 weeks. Glucose tolerance, fasting blood glucose, and
plasma insulin levels were normal at 9 weeks in DGKd+/ mice
(Figures 4B and 4C and Table S3). In contrast, glucose tolerance
Figure 3. DGK Protein Expression and
Activity in DGKd Haploinsufficient Mice
(A–C) DGKd protein expression in (A) gastrocne-
mius muscle, (B) epidydimal fat, and (C) liver in
DGKd+/ mice versus WT mice at 9 weeks of age.
(D) Total DGK activity, per gram of tissue protein,
in homogenates prepared from gastrocnemius
muscle, epidydimal fat, and liver.
(E) Total DGK activity per gram of tissue protein in
homogenate (Hom), crude membrane fraction
(Membr), and cytoplasmic (Cyto) fraction isolated
from gastrocnemius muscle from 9-week-old
DGKd+/ mice. Results are mean ± SEM for n =
7–15animals. *p<0.05versus9-week-oldWTmice.
was significantly impaired at 36 weeks in
DGKd+/ mice (Figures 4B and 4C), com-
pared with age-matched littermates. In
older WTmice, insulin levels in the fasting
state, as well as during the IPGTT, were
also elevated compared to younger WT
mice, indicative of development of insulin
resistance. Glucose tolerance was impaired and insulin levels
were elevated in DGKd+/mice compared to age-matched litter-
mates. These age-associated changes in glucose homeostasis
were independent of any further reduction in DGKd expression
or total DGK activity (Figures 4D and 4E). Skeletal muscle DAG
levels were increased by 40% in DGKd+/ mice (Figure 4F),
underscoring the contribution of DGKd to skeletal muscle DAG
homeostasis. In contrast, DAG levels were unaltered in liver of
DGKd+/ mice (Figure S6), indicating that this isoform plays a
minor role in total DGK activity in liver.
Insulin-stimulated glucose transport was assessed in isolated
soleus muscle at 9 and 36 weeks in WT and DGKd+/ mice
(Figure 4G). Despite normal fasting insulin, glucose tolerance,
and body weight in DGKd+/ mice at 9 weeks, insulin-stimulated
glucose transport in response to 0.36 nM, but not 120 nM, was
decreased in isolated soleus muscle. Moreover, the impairment
in skeletal muscle insulin-stimulated glucose transport was
observed prior to the development of obesity, hyperinsulinemia,
or glucose intolerance. An impairment in submaximal (0.36 nM),
but not maximal (120 nM), insulin-stimulated glucose transport
was noted in WT mice at 36 weeks. In DGKd+/ mice, basal glu-
cose transport was unaltered at 36 weeks, but insulin-stimulated
glucose transport was impaired, concomitant with obesity,
hyperinsulinemia, and glucose intolerance, compared to age-
matchedWT littermates. Skeletal muscle GLUT4 protein expres-
sion was unaltered between WT and DGKd+/ mice.
Consequence of DGKd Haploinsufficiency on Peripheral
Insulin Sensitivity and Signaling
Since glucose uptake in skeletal muscle and adipose tissue
accounts for the majority of peripheral glucose disposal, we
examined tissue-specific responses for glucose uptake in vivo
during a euglycemic-hyperinsulinemic clamp in conscious
mice. We studied 9-week-old mice to avoid the potential
deleterious effect of hyperinsulinemia and/or obesity on whole-
body insulin-mediated glucose homeostasis, as these factorsCell 132, 375–386, February 8, 2008 ª2008 Elsevier Inc. 379
Figure 4. DGKd Haploinsufficiency Leads to Glucose Intolerance and Obesity
(A) Body weight and epidydimal fat pad weight of DGKd+/ and WT mice at 9 and 36 weeks.
(B and C) Glucose (B) and insulin (C) during glucose tolerance in overnight fasted mice.
(D) Skeletal muscle lysates were subjected to immunoblot analysis using an antibody against DGKd. Upper panel is representative image and lower panel is
mean ± SEM, arbitrary units. *p < 0.05 versus WT.
(E and F) Total DGK activity (E) and DAG content (F) in skeletal muscle homogenate. Results are mean ± SEM.
(G) Basal and insulin-stimulated in vitro 2-deoxyglucose uptake in isolated soleus muscle from WT and DGKd+/ mice. Results are mean ± SEM for 8–12 mice.
*p < 0.05 versus WT mice at 9 weeks, #p < 0.05 versus WT mice at 36 weeks.independently contribute to insulin resistance. Euglycemic-
hyperinsulinemic clamps were performed in separate experi-
ments using either a low (1.25 mU/min/kg; Figure 5A) or high
(10 mU/min/kg; Figure 5B) dose insulin infusion. Under the
low-dose insulin infusion (Figure 5A), plasma insulin levels were
increased 2-fold (0.2 ± 0.1 versus 0.4 ± 0.06 ng/ml). Insulin-
mediated peripheral glucose utilization was increased 66% ver-
sus 18% over basal in WT versus DGKd+/ mice, respectively,
whereas the hepatic insulin response was similar between
genotypes. Under the high dose insulin infusion (Figure 5B),
plasma insulin levels were markedly increased (0.4 ± 0.1 versus
5.2 ± 0.4 ng/ml), and hepatic glucose output was completely
inhibited in both genotypes. Similar to results for the low-dose
insulin infusion, peripheral glucose utilization was impaired in
DGKd+/ mice.
In vivo tissue-specific glucose uptake was also determined in
separate experiments under the high-dose insulin infusion (Fig-
ures 5C and 5D). In DGKd+/ mice, insulin-stimulated glucose
uptake (Figure 5C) was significantly decreased in EDL (34%)380 Cell 132, 375–386, February 8, 2008 ª2008 Elsevier Inc.and soleus (21%) and tended to be decreased in gastrocnemius
(36%, p = 0.09), diaphragm (36%, p = 0.12), and heart (29%,
p = 0.07) muscle. Insulin-mediated glucose uptake was also sig-
nificantly decreased in white adipose tissue (50%) but not brown
adipose tissue (BAT) (Figure 5D). The impaired skeletal muscle
glucose uptake was associated with reduced insulin-stimulated
tyrosine phosphorylation of IR and IRS-1 and serine/threonine
phosphorylation of Akt and AS160, components of the canonical
insulin signaling cascade important for glucose uptake and
metabolism (Figure 5E). In contrast, liver insulin-stimulated
phosphorylation of IR, IRS-1, IRS-2, and Akt was similar between
DGKd+/ and WT mice (Figure 5F). Thus, DGKd+/ mice develop
insulin resistance in skeletal muscle and adipose tissue, but not
liver, prior to development of obesity, glucose intolerance, and
hyperinsulinemia. Since defects in glucose uptake were ob-
served in isolated skeletal muscle, as well as at the whole-
body level, DGKd expression directly influences skeletal muscle
insulin sensitivity independent of alterations in the metabolic
milieu.
Figure 5. DGKd Haploinsufficiency Impairs Peripheral Insulin Sensitivity and Signaling
(A and B) In vivo glucose utilization during euglycemic-hyperinsulinemic clamp under low (A; 1.25 mU/min/kg) or high (B; 10 mU/min/kg) dose insulin infusion in
9-week-old DGKd+/ and WT mice.
(C and D) In vivo insulin-stimulated glucose uptake in (C) skeletal and cardiac muscle (D) and subcutaneous (SubqAT), epidydimal (EpiAT), and brown adipose
tissues (BAT) after high-dose insulin infusion.
(E and F) Insulin signal transduction in skeletal muscle (E) or liver (F) measured after high-dose insulin infusion. Upper panel is representative image and lower
panel is mean ± SEM, arbitrary units. Results are mean ± SEM for n = 7–9 mice. *p < 0.05 versus WT mice.Skeletal Muscle Lipid Oxidation andWhole-Body Energy
Homeostasis Are Altered in DGKd+/ Mice
We next determined whether DGKd expression influences skel-
etal muscle lipid metabolism or whole-body energy homeosta-
sis. Skeletal muscle triglyceride content and plasma nonesteri-
fied fatty acid were unaltered between genotypes (Table S3);
however, oleate oxidation was reduced 30% in isolated soleus
muscle from 9-week-old DGKd+/ mice (Figure 6A). Whole-
body energy homeostasis was also determined through analysis
of food intake, locomotor activity, oxygen consumption, and
respiratory exchange ratio (RER). Although food intake and loco-
motor activity did not differ between genotypes over a 24 hr pe-
riod (Figures 6B and 6C), oxygen consumption (VO2; ml/kg/hr)
was reduced in DGKd+/ mice (Figure 6D). RER was determinedin the light and dark cycles, when animals were in a rested and
active state, respectively. DGKd+/ mice failed to appropriately
shift between lipid and glucose oxidation in the transition be-
tween the light (rested) and dark (active) states (Figure 6E),
thereby demonstrating ‘‘metabolic inflexibility.’’ Changes in skel-
etal muscle oleate oxidation and whole-body energy homeosta-
sis were observed prior to the development of obesity.
Signaling Impairments in Skeletal Muscle
from DGKd+/ Mice
Elevations in DAG have been linked to increased PKC activity
and serine phosphorylation of IRS-1, constituting a negative
feedback regulation along insulin signaling cascades governing
glucose and lipid metabolism (Itani et al., 2002; Yu et al.,Cell 132, 375–386, February 8, 2008 ª2008 Elsevier Inc. 381
2002). Expression and phosphorylation of DAG-dependent
PKCs and IRS-1 were determined in skeletal muscle (Figure 7)
and liver (Figure S6) from DGKd+/ mice and WT littermates.
Phosphorylation and expression of PKC q and h were unaltered
in skeletal muscle from DGKd+/mice. Phosphorylation of PKCd
was increased in skeletal muscle fromDGKd+/mice (Figure 7A),
similar to the effect of DGK inhibition by R59949. Protein expres-
sion of IR and IRS-1 (Figures 7B and 7C)was reduced in DGKd+/
mice at 9 weeks but not 36 weeks. IR and IRS-1 expression in
both genotypes at 36 weeks was lower compared to 9 weeks.
IRS-1 Ser307 phosphorylation normalized to the level of IRS-1
protein expression was increased in DGKd+/ mice (Figure 7D).
Figure 6. Skeletal Muscle Lipid Oxidation
and Whole-Body Energy Homeostasis
Impairments in DGKd+/ Mice
(A) Oleate oxidation in isolated soleusmuscle from
fed DGKd+/ and WT mice.
(B) Food intake assessed over 24 hr.
(C) Locomotor activity assessed over 24 hr.
(D) Whole-body oxygen consumption (VO2) as-
sessed over 24 hr.
(E) Respiratory exchange ratio assessed over
24 hr, during the light (sedentary) and dark (active)
cycles.
Results are mean ± SEM, *p < 0.05 versus WT
mice.
Figure 7. Signaling Impairments in Gastrocnemius Muscle from DGKd+/ Mice
(A–D) Muscle lysates were subjected to immunoblot analysis for (A) PKCd Thr505 phosphorylation, (B) IR protein and actin (loading control), (C and D) IRS-1
protein/IRS-1 Ser307 phosphorylation in W mice and DGKd+/ mice at 9 and 36 weeks. Upper panel shows representative image. Graphs are mean ± SEM,
*p < 0.05 versus 9-week-old WT mice.
In stark contrast to the phenotype
described for skeletal muscle, liver DAG
content, PKCd phosphorylation, and IR
and IRS protein expression were un-
altered in DGKd+/mice (Figure S6). Liver
insulin signaling was unaltered in
DGKd+/ mice after the euglycemic-
hyperinsulinemic clamp, consistent with
the observation that peripheral, but not hepatic, insulin sensitivity
was impaired. Collectively these data indicate that a reduction in
DGKd impairs insulin signaling in skeletal muscle.
Genetic Analysis of DGKD
We analyzed quantitative traits for the DGKD gene in 234 off-
spring of type 2 diabetic patients who had a nondiabetic oral
glucose tolerance test. One of the parents had to have type 2
diabetes and the other had to exhibit normal glucose tolerance.
Nine single-nucleotide polymorphisms (SNPs) properly covering
the promoter and coding regions of DGKD were screened. Dif-
ferent SNPs had a nominal association (p < 0.05) with insulin382 Cell 132, 375–386, February 8, 2008 ª2008 Elsevier Inc.
area under the curve (AUC) in a 2 hr oral glucose tolerance test,
glucose AUC during the intravenous glucose tolerance test
(IVGTT), and insulin AUC from 10 to 60 min in an IVGTT (Table
S4). No association was observed between DGKD SNPs and in-
sulin sensitivity, as measured by the euglycemic clamp.
DISCUSSION
Intracellular DAG levels are elevated in skeletal muscle from in-
sulin-resistant rodents and humans (Itani et al., 2002; Kraegen
et al., 2006), suggesting a role for lipid intermediates in the devel-
opment of insulin resistance. DGK isoforms modulate the bal-
ance between DAG and PA levels and terminate DAG signals
through the conversion of DAG to PA (Sakane et al., 2007;
Topham, 2006). DGK isoforms interact with specific isoforms
for PKC, RasGRP, and PI kinases to regulate numerous biologi-
cal events including cell growth, neuronal transmission, and cy-
toskeleton remodeling (Sakane et al., 2007; Topham, 2006). We
reveal a previously unrecognized role for DGKd in contributing to
hyperglycemia-induced insulin resistance and impairments in
energy homeostasis, thereby exacerbating the severity of type
2 diabetes. Reduced DGKd activity, either by chemical inhibition
or by genetic ablation of the enzyme using DGKd+/ mice,
caused aberrant insulin signaling, glucose uptake defects in
skeletal muscle and adipose tissue, impaired whole-body insulin
resistance, and obesity. Our findings in DGKd+/ mice demon-
strate that reduced DGKd expression directly causes peripheral
insulin resistance, metabolic inflexibility, mild obesity, and
further metabolic derangements.
Skeletal muscle protein expression of DGKd and total DGK
activity was reduced in type 2 diabetic patients and diabetic ro-
dents and normalized upon correction of hyperglycemia. This
finding strongly suggests that DGKd undergoes downregulation
as a consequence of the altered metabolic milieu. Indeed DGKd,
but not a, 3, or z, protein expression was negatively correlated
with fasting glucose and HbA1c. These defects were localized
to peripheral, rather than hepatic, tissues. Although variations at
the DGKD locus are unlikely to constitute a major genetic cause
of type 2 diabetes (Saxena et al., 2007; Sladek et al., 2007), we
found suggestive evidence that SNPs of DGKD are associated
with altered glucose metabolism in offspring of type 2 diabetic
subjects. DGKd appears to play an important role in metabolic
regulation since environmental factors can also contribute to reg-
ulation of insulin sensitivity in type 2 diabetes. Exercise training-
induced improvements in insulin sensitivity have been positively
correlatedwith an increase in skeletalmuscleDGKdgeneexpres-
sion in nondiabetic (Teran-Garcia et al., 2005) and type 2 diabetic
(Fritz et al., 2006) people, highlighting a potential role of this en-
zyme in the regulation of metabolism in response to regular exer-
cise. Rare genetic defects inDGKD have been observed; a recent
case studyof a12-year-old-femalewithepilepsyprovidesgenetic
support that disruptiononDGKD is associatedwith seizures, cap-
illary abnormality, developmental delay, infantile hypotonia, and
obesity (Leach et al., 2007). While the DGKd+/ mice studied
here also displayed an obesity phenotype with aging, they did
not display any obvious growth defects or sign of seizures.
Insulin sensitivity is impaired in younger DGKd+/mice that are
not obese and have yet to show any signs of hyperglycemia,glucose intolerance, systemic hyperinsulinemia, or alterations
in food intake and locomotor activity. DGKd haploinsufficiency
can cause ‘‘primary’’ peripheral insulin resistance, impaired lipid
oxidation, and impaired energy homeostasis, which leads to
obesity in later life. Insulin-mediated glucose uptake and un-
coupling protein 1 protein expression in BAT were unaltered
between genotypes, providing evidence against metabolic alter-
ations in BAT as a cause of the obesity phenotype in DGKd+/
mice. Furthermore, hypothalamic mRNA expression of neuro-
peptides including neuropeptide Y, proopiomelanocortin, and
agouti-related protein is unaltered in DGKd+/ mice, despite
mild obesity and insulin resistance with aging. These results do
not preclude an effect of DGKd in energy homeostasis via
actions in other tissues.
The reduction in DGKd expression and activity appears to pro-
mote peripheral insulin resistance and metabolic inflexibility,
whichmay contribute to the obesity phenotype.Metabolic inflex-
ibility, as defined by an inability to appropriately transition
between lipid and carbohydrate oxidation, has been linked to
impaired oxidative capacity in insulin resistance and type 2
diabetes (Storlein et al., 2004). Impaired oleate oxidation and pe-
ripheral insulin-mediated glucose uptake in DGKd+/ mice were
associated with increased adipose mass and increased body
weight, which further contributed to the development of glucose
intolerance. These defects may arise from alterations in mito-
chondrial size and density, expression of oxidative enzymes, or
changes in skeletal muscle fiber type. Therefore, DGKd+/
mice resemble many of the features associated with the clinical
manifestation of peripheral insulin resistance in type 2 diabetes
in humans.
Disruption of insulin signaling events associated with GLUT4
translocation impairs glucose transport (Ishiki and Klip, 2005).
Based on our clinical and experimental studies, we describe
a signal transduction pathway involving DAG-induced insulin re-
sistance as a result of impaired DGKd expression and activity. In
addition to a local increase in DAG, a decrease in DGKd expres-
sion and DGK activity leads to a concomitant decrease in PA
levels. DGK enzymes act as both terminators of DAG-mediated
signals and activators of PA-mediated signals. Protein targets of
PA include positive regulators of glucose transport, such as
PKCz, and membrane vesicle traffic, such as phosphatidylinosi-
tol 4-phosphate 5-kinase (Sakane et al., 2007; Topham and Pre-
scott, 1999). Interestingly, insulin-independent glucose transport
was unaltered by DGK inhibition. Nevertheless, we cannot
exclude the possibility that the reduction of DGKd contributes
to the regulation of glucose transport through regulating the
production of PA.
The increase in DAG mass and PKC activity offers a possible
mechanism for the decreased insulin signaling in DGKd+/
mice. The impairment in whole-body insulin-mediated glucose
uptake may be attributed to DAG accumulation, elevated PKC
activity, and serine phosphorylation of IRS-1, leading to periph-
eral insulin resistance and impaired energy homeostasis. Re-
duced membrane-associated DGK activity may change subcel-
lular localization and compartmentalization of important signal
transducers and contribute to an altered metabolic response.
Confirming an effect of DGKd deficiency on tyrosine receptor-
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epidermal growth factor receptor threonine phosphorylation and
reduces receptor expression and activity in keratinocytes from
DGKd null mice (Crotty et al., 2006). This provides a link between
DGKd, PKCs, and consequently EGFR and insulin signaling
pathways. Interestingly, differences between chemical inhibition
of DGK and heterozygosity for DGKd with respect to IR expres-
sion and phosphorylation were noted, suggesting that reduced
IR protein expression in DGKd+/ mice may arise from chronic
transcriptional effects as observed for EGFR in DGKd null
mice. Our results cannot exclude the possibility that reduced
IR expression contributes to the observed impairments in insulin
sensitivity and glucose homeostasis in DGKd+/ mice. Muscle-
specific IR dominant-negative transgenic mice (Chang et al.,
1994; Moller et al., 1996) or IR null mice (Bruning et al., 1998)
develop mild obesity secondary to defects in skeletal muscle
insulin action.
Reduced DGKd protein expression directly contributes to the
development of peripheral insulin resistance and mild obesity.
Data from DGKd+/ mice support this concept, as a 50% reduc-
tion in DGKd protein expression induces peripheral insulin resis-
tance and mild obesity in the absence of hyperglycemia. Re-
duced DGKd protein expression can act as a primary mediator
of insulin resistance in type 2 diabetes and promote mild obesity
with aging. Data fromdiabetic GK rats also provide evidence that
insulin resistance occurs in concert with hyperglycemia-induced
downregulation of DGKd. In this case, the reduction in DGKd pro-
tein occurs in response to hyperglycemia or other environmental
factors, which secondarily impact DGKd expression and DAG
metabolism. Collectively, our findings highlight a role for DGKd
in the regulation of hyperglycemia-induced impairments in
peripheral insulin sensitivity and reveal new insight into how to
resolve themetabolic complexities associatedwith type 2 diabe-
tes mellitus. Therapeutic approaches to target DAG and PA me-
tabolism via regulation of DGKd may control and prevent insulin
resistance in metabolic disease.
EXPERIMENTAL PROCEDURES
Human Studies for Muscle Analysis
Subjects were matched for age, BMI, and physical fitness. Skeletal muscle
biopsies were obtained from the vastus lateralis portion of the quadricepsmus-
cle from 11 type 2 diabetic and 11 healthy control subjects (Table S2) with ap-
proval from the institutional ethical committee of Karolinska Institutet. Studies
were performed according to the declaration of Helsinki and informed written
consent was obtained. Type 2 diabetic subjects were treated with diet, sulfo-
nylureas, or metformin. Individuals taking beta-adrenergic receptor blockers,
ACE inhibitors, or hormonal therapy were excluded from the study. Skeletal
muscle lysates were prepared and subjected to immunoblot analysis as
described (Krook et al., 2000).
Subjects and Phenotype Analysis for Genetic Studies
The aim of this study was to investigate the association of SNPs of DGKD with
parameters of glucose metabolism. The collection of subjects and the study
protocol for our offspring study have been previously published (Salmenniemi
et al., 2004), and a summary is available (Supplemental Experimental Proce-
dures). The study protocol was approved by the Ethics Committee of the Uni-
versity of Kuopio. All subjects gave an informed consent. The mean age and
body mass index of the subjects was 35 years and 26 kg/m2, respectively,
and all had nondiabetic glucose tolerance. Subjects underwent the following
studies: an OGTT (n = 234), a euglycemic-hyperinsulinemic clamp (n = 217)
to evaluate insulin sensitivity, and an intravenous glucose tolerance test384 Cell 132, 375–386, February 8, 2008 ª2008 Elsevier Inc.(IVGTT) (n = 217) to evaluate the first phase insulin secretion. Selection of
SNPs of DGKD was based on the genotype data from Utah residents with an-
cestry from Northern and Western Europe available from HapMap project’s
website (Public Release #20, January 24, 2006) (Altshuler et al., 2005). Geno-
typing and statistical analysis are described (Supplemental Experimental
Procedures).
Animal Studies
Animals were maintained in a temperature- and light-controlled environment
and were cared for in accordance with regulations for the protection of labora-
tory animals. The regional animal ethical committee approved all experimental
procedures. Animals were maintained under a 12 hr light:dark cycle and had
free access to water and standard rodent chow.
Goto Kakizaki Rats and Treatment
Male GK and weight-matched Wistar rats (200–250 g) from Karolinska Institu-
tet were treated with phlorizin (0.8 g/kg body weight per day; as 40% solution
in propylene glycol) or vehicle (equal amounts of propylene glycol per kilogram)
for 4 weeks (Krook et al., 1997). Gastrocnemious muscle and liver were dis-
sected and frozen in liquid nitrogen. Plasma insulin and glucose tolerance
was previously determined (Krook et al., 1997).
EpitrochlearisMuscle Incubation and Glucose Transport
Male Wistar rats (120–140 g) were obtained from B&K Universal, Sollentuna,
Sweden. Rats were anesthetized with pentobarbital and epitrochlearis mus-
cles were dissected free and incubated for insulin signaling and glucose trans-
port. Muscles were preincubated for 30min either with 50 mmol/l DGK inhibitor
I R59022, 25 mmol/l DGK inhibitor II R59949, 1 mmol/l Phorbol-12-Myristate-
13-Acetate (PMA), or broad spectrum PKC inhibitor GF109203X (1 mmol/l)
(Calbiochem). Muscle was incubated for 30 min (Wallberg-Henriksson, 1987)
in the absence or presence of 2.4 nmol/l insulin (Actrapid, Novo Nordisk) or
incubated under a nitrogen gas phase (hypoxia) in the absence or presence
of inhibitors. After incubation, muscles were frozen in liquid nitrogen for subse-
quent glucose transport and insulin signaling analysis. Glucose transport
activity was assessed (Wallberg-Henriksson, 1987).
Generation of DGKd Haploinsufficient Mice
The description of the methods used to generate haploinsufficient DGKd
(DGKd+/) mice is presented in Crotty et al. (2006).
Glucose Tolerance Test and Metabolic Analysis in DGKd+/ Mice
Glucose (1 g/kg body weight) was administered to fasted DGKd+/ mice and
WT littermates by intraperitoneal injection (Supplemental Experimental Proce-
dures). Plasma insulin, NEFA, adiponectin, leptin, and resistin were deter-
mined (Supplemental Experimental Procedures). 2-deoxy-glucose uptake
and oleate oxidation were assessed in isolated mouse soleus muscle (Barnes
et al., 2004). Triglyceride content was determined in mouse gastrocnemius
muscle using a triglycerides/glycerol blanked kit (Roche, Stockholm, Sweden)
and a Seronorm lipid (SERO A/S, Oslo, Norway) standard.
Whole-Body Energy Homeostasis in DGKd+/ Mice
Food intake, oxygen consumption, RER, and locomotor activity were mea-
sured using a Comprehensive Lab Animal Monitoring System (Columbus
Instruments, Columbus, OH, USA), (Supplemental Experimental Procedures).
Euglycemic-Hyperinsulinemic Clamp in Conscious in DGKd+/ Mice
Glucose turnover rate (GTR) wasmeasured in the basal state and during eugly-
cemic and hyperinsulinemic conditions, using a constant infusion of [3-3H]glu-
cose (Supplemental Experimental Procedures). Basal glucose production and
utilization were assessed. Gastrocnemius muscle and liver were immediately
frozen in liquid nitrogen for insulin signaling analysis.
Insulin-Stimulated Tissue-Specific Glucose Uptake in DGKd+/Mice
Animals were studied as described above for the Euglycemic-Hyperinsuline-
mic Clamp procedure. 2-deoxy-D-[1-14C]glucose was administered to esti-
mate insulin-stimulated glucose uptake and metabolism in different tissues
(Supplemental Experimental Procedures).
Analytical Procedures
Total DGK activity was determined (Lee et al., 1999) (Supplemental Experi-
mental Procedures). Phosphorylation and expression of protein signaling in-
termediates and PI 3-kinase activity was assayed (Krook et al., 2000). Skeletal
muscle and liver DAG content was determined by conversion to phosphoryla-
tion products by externally added DAG-kinase from E. coli in the presence of
[g-32P] ATP (Preiss et al., 1986). Total conventional and novel PKC activity was
measured in muscle homogenates without addition of exogenous DAG
(Kikkawa et al., 1983). The specificity of the DGK inhibitor was tested against
a panel of 30 different protein kinases (Figure S4) (Davies et al., 2000).
Statistics
Differences between groups were determined by ANOVA with multiple
comparisons with Fischer’s post hoc analysis. Student’s t test was used for
comparisons when only two parameters were evaluated. Correlations were
determined using Pearson’s Correlation Analysis. Significance was accepted
at p < 0.05.
Supplemental Data
Supplemental Data include Experimental Procedures, four tables, and six
figures and can be found with this article online at http://www.cell.com/cgi/
content/full/132/3/375/DC1/.
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